Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Rejection-associated Phenotype of De Novo Thrombotic Microangiopathy Represents a Risk for Premature Graft Loss

V. Petr, P. Hruba, M. Kollar, K. Krejci, R. Safranek, S. Stepankova, J. Dedochova, J. Machova, J. Zieg, J. Slatinska, E. Pokorna, O. Viklicky

. 2021 ; 7 (11) : e779. [pub] 20211022

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22001487

Background: Thrombotic microangiopathy (TMA) significantly affects kidney graft survival, but its pathophysiology remains poorly understood. Methods: In this multicenter, retrospective, case-control paired study designed to control for donor-associated risks, we assessed the recipients' risk factors for de novo TMA development and its effects on graft survival. The study group consists of patients with TMA found in case biopsies from 2000 to 2019 (n = 93), and the control group consists of recipients of paired kidney grafts (n = 93). Graft follow-up was initiated at the time of TMA diagnosis and at the same time in the corresponding paired kidney graft. Results: The TMA group displayed higher peak panel-reactive antibodies, more frequent retransplantation status, and longer cold ischemia time in univariable analysis. In the multivariable regression model, longer cold ischemia times (odds ratio, 1.18; 95% confidence interval [CI], 1.01-1.39; P = 0.043) and higher peak pretransplant panel-reactive antibodies (odds ratio, 1.03; 95% CI, 1.01-1.06; P = 0.005) were found to be associated with increased risk of de novo TMA. The risk of graft failure was higher in the TMA group at 5 y (hazard ratio [HR], 3.99; 95% CI, 2.04-7.84; P < 0.0001). Concomitant rejection significantly affected graft prognosis at 5 y (HR, 6.36; 95% CI, 2.92-13.87; P < 0.001). De novo TMA associated with the active antibody-mediated rejection was associated with higher risk of graft failure at 5 y (HR, 3.43; 95% CI, 1.69-6.98; P < 0.001) compared with other TMA. Conclusions: Longer cold ischemia and allosensitization play a role in de novo TMA development, whereas TMA as a part of active antibody-mediated rejection was associated with the highest risk for premature graft loss.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22001487
003      
CZ-PrNML
005      
20220112153617.0
007      
ta
008      
220107s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/TXD.0000000000001239 $2 doi
035    __
$a (PubMed)34712779
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Petr, Vojtech $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
245    10
$a Rejection-associated Phenotype of De Novo Thrombotic Microangiopathy Represents a Risk for Premature Graft Loss / $c V. Petr, P. Hruba, M. Kollar, K. Krejci, R. Safranek, S. Stepankova, J. Dedochova, J. Machova, J. Zieg, J. Slatinska, E. Pokorna, O. Viklicky
520    9_
$a Background: Thrombotic microangiopathy (TMA) significantly affects kidney graft survival, but its pathophysiology remains poorly understood. Methods: In this multicenter, retrospective, case-control paired study designed to control for donor-associated risks, we assessed the recipients' risk factors for de novo TMA development and its effects on graft survival. The study group consists of patients with TMA found in case biopsies from 2000 to 2019 (n = 93), and the control group consists of recipients of paired kidney grafts (n = 93). Graft follow-up was initiated at the time of TMA diagnosis and at the same time in the corresponding paired kidney graft. Results: The TMA group displayed higher peak panel-reactive antibodies, more frequent retransplantation status, and longer cold ischemia time in univariable analysis. In the multivariable regression model, longer cold ischemia times (odds ratio, 1.18; 95% confidence interval [CI], 1.01-1.39; P = 0.043) and higher peak pretransplant panel-reactive antibodies (odds ratio, 1.03; 95% CI, 1.01-1.06; P = 0.005) were found to be associated with increased risk of de novo TMA. The risk of graft failure was higher in the TMA group at 5 y (hazard ratio [HR], 3.99; 95% CI, 2.04-7.84; P < 0.0001). Concomitant rejection significantly affected graft prognosis at 5 y (HR, 6.36; 95% CI, 2.92-13.87; P < 0.001). De novo TMA associated with the active antibody-mediated rejection was associated with higher risk of graft failure at 5 y (HR, 3.43; 95% CI, 1.69-6.98; P < 0.001) compared with other TMA. Conclusions: Longer cold ischemia and allosensitization play a role in de novo TMA development, whereas TMA as a part of active antibody-mediated rejection was associated with the highest risk for premature graft loss.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hruba, Petra $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kollar, Marek $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Krejci, Karel $u 3rd Department of Internal Medicine-Nephrology, Rheumatology and Endocrinology, Teaching Hospital Olomouc, Czech Republic
700    1_
$a Safranek, Roman $u Hemodialysis Centre, Teaching Hospital Hradec Kralove, Czech Republic
700    1_
$a Stepankova, Sona $u Centre for Cardiovascular and Transplantation Surgery, Brno, Czech Republic
700    1_
$a Dedochova, Jarmila $u Department of Medicine, Teaching Hospital Ostrava, Czech Republic
700    1_
$a Machova, Jana $u Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, Teaching Hospital Pilsen, Czech Republic $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Zieg, Jakub $u Department of Paediatrics, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
700    1_
$a Slatinska, Janka $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Pokorna, Eva $u Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Viklicky, Ondrej $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
773    0_
$w MED00195744 $t Transplantation direct $x 2373-8731 $g Roč. 7, č. 11 (2021), s. e779
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34712779 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220107 $b ABA008
991    __
$a 20220112153613 $b ABA008
999    __
$a ind $b bmc $g 1745498 $s 1152634
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 7 $c 11 $d e779 $e 20211022 $i 2373-8731 $m Transplantation direct $n Transplant Direct $x MED00195744
LZP    __
$a Pubmed-20220107

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace